Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar
(Reuters) - Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose.
The news sent Eisai’s shares up as much as 14.6 percent in Friday morning trading in Tokyo while Biogen’s shares were up 7 percent at $320 in after-hours trading.
Biogen and Eisai said in their statement on Thursday that detailed results of the final analysis of the mid-stage trial will be released at future conferences.
There is still no treatment that can slow the progression of Alzheimer’s, the commonest form of dementia. Current drugs can do no more than ease some of the symptoms.